Effect Of Coronary Atherosclerotic Plaque By Rosuvastatin: A Meta-analysis

Objective: To evaluate the effect of rosuvastatin in coronary atherosclerosis patients and antiatherosclerotion under the Intravascular ultrasound(IVUS).Method:We conducted a systematic search for clinical trials pertaining to the effect of rosuvastatin in coronary atherosclerosis patients.The search was performed on PubMed,EMBASE,Cochrane Library,and CBM databases.Relevant references(up to March 2019)were retrieved and subsequent results analyzed with a random-effects model or a fixed-effects model.Result:A total of ten clinical trials with a sample size of 1741 patients,were identified and incorporated in this study.In terms of coronary plaque effects,patients receiving rosuvastatin exhibited decreased total atheroma volume(TAV)(MD=-0.60,P=0.03),normalized external elastic membrane(EEM)(MD=-0.80,P=0.03)and percent atheroma volume(PAV)(MD=-1.03,P=0.0005).Those patients had a significantly modulate lipid levels(total cholesterol(TC): SMD=-1.72,P<0.00001;Triglyceride(TG): SMD=-0.42,P<0.00001;high density lipoprotein cholesterol(HDL-C): MD=0.50,P<0.00001;low density lipoprotein cholesterol(LDL-C): SMD=-1.20,P>0.00001];MD=-57.11,P<0.00001)(OR=0.05,P=0.04)compared to those in the control group.The results indicated no significant differences in Plaque Volume(MD=-4.65,P=0.19).Conclusion: Use of rosuvastatin in coronary atherosclerosis patients could modulate lipid levels,accompanied decrease TAV,EEM,PAV.It showed a cardiovascular protection.Further large-sampled studies are needed to support these findings.